Lachema Optimistic About 1994

24 October 1994

Pharmaceutical and chemicals producer Lachema of the Czech Republic is expected to achieve turnover of 900 million crowns ($32.1 million) in 1994, an increase of 12.5% on turnover achieved in 1993, reports the CTK news agency's Business News. Pharmaceuticals account for 60% of the company's output.

Lachema is planning to substantially increase its pharmaceutical and chemical production over the next eight years, and will increase its workforce by 20% from the current 1,170 employees, according to the report.

This optimism is based on a better business environment, which is reflected in a recently-signed five-year agreement to export the company's products to the UK. Lachema, which already exports 60% of its production, is also looking towards the Russian market, where it hopes to develop barter trade.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight